Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 42M | 21M | 6M | 1M | 0 |
| Gross Profit | 18M | 8M | 713K | 490K | -19K |
| Operating Income | -8M | -19M | -21M | -6M | -1M |
| EBITDA | -7M | -18M | -20M | -5M | -1M |
| Net Income | -12M | -19M | -21M | -6M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.36
-4.82% today
1Y Change
-40.53%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SS Innovations International, Inc. (SSII) is a Healthcare stock with a market cap of $800.00M and listed on NASDAQ. The stock last traded around $3.36 and down 40.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +105.4%, EPS growth of +42.0%, a dividend yield of 0.0%. What stands out right now is revenue +105.4%, EPS +42.0%, free cash flow -118.4% with operating margin -19.7% and ROIC -17.2%. Valuation already assumes a fairly strong business story at price/sales 18.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SSII price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SSII
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SSII Max Drawdown
-66.73%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SSII and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$1.5M
+73.5% YoY
Free Cash Flow
-$363.0K
+74.7% YoY
Revenue Growth
+105.4%
EPS Growth
+42.0%
Gross Margin
45.3%
Net Margin
-28.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 42M | 21M | 6M | 1M | 0 |
| Gross Profit | 18M | 8M | 713K | 490K | -19K |
| Operating Income | -8M | -19M | -21M | -6M | -1M |
| EBITDA | -7M | -18M | -20M | -5M | -1M |
| Net Income | -12M | -19M | -21M | -6M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 467K | 7M | 217K | 406K |
| Total Assets | 74M | 42M | 25M | 7M | 429K |
| Total Liabilities | 36M | 29M | 11M | 10M | 287K |
| Shareholder Equity | 38M | 13M | 14M | -3M | 141K |
| Total Debt | 3M | 18M | 8M | 8M | 145K |
| Net Debt | -290K | 18M | 1M | 8M | -261K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
363K
+93.9% YoY
Capital Expenditures
0
-100.0% YoY
Free Cash Flow
363K
+74.7% YoY
Key ratios
Gross Margin
45.3%
Operating Margin
-19.7%
Net Margin
-28.6%
ROE
-30.2%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.